 The current standard treatment approach for young patients with Positive Acute Lymphoblastic Leukemia PhALL is the combination of a chemotherapy protocol employing four to five cytotoxic agents typically used for ALL together with imatinib. It is recommended to propose allogeneic Standard Induction and Consolidation Therapy SCT to all eligible patients with a suitable donor and to continue imatinib with or without additional therapy in patients not undergoing SCT. 